This is the re-test for Physician Focus on Parkinson's Issue 20 (Winter 2011). A score of 70% or better must be obtained in order to receive your CME certificate for participating in this activity.
|
| According to a study of PD patients on COMT inhibitors, how did COMT genotype affect response to therapy? |
|
Based on the results of the COMT genotype study, do you feel it is now appropriate to genotype PD patients before beginning COMT inhibitor therapy?
|
| What role does the physicians enthusiasm and encouragement play in a patient's decision to get involved in a clinical trial? |
|
| What is the rationale for glutamic acid decarboxylase (GAD) gene therapy in PD? |
|
| According to a new study, what is the potential significance that neurons take up alpha-synuclein (AS), leading to protein aggregation? |
|
| In that study, what was the significance of the release of AS by dying cells? |
|
A newly diagnosed patient asks you whether there are any experimental treatments for PD that would be appropriate for her. What information, resources, and advice would you give the patient?
|
| According to a study of GAD gene therapy, treatment with GAD-AAV: |
|
| According to a 10-year follow-up study of deep brain stimulation, symptoms of ______ were the most amenable to stimulation improvement, while _____ were more resistant. |
|
| Botulinum toxin therapy may benefit PD patients who drool because: |
|